Antiatherogenic effect of pyridinolcarbamate (prodectin). Experimental study.
The experimental study was performed on Wistar rats fed on atherogenic diet for 16 months, the last 70 days of which they were given Prodectin. The study included also Chinchilla rabbits fed on cholesterol-rich diet (CRD) and Prodectin for 5 months. The data obtained showed that the continuous application of Prodectin inhibited the development of cholesterol-induced atherosclerosis both in rats and rabbits. The decrease of plasma lipids, the increased activity of the Krebs cycle enzymes as well as the lowered ADP-platelet aggregation and the decreased endothelial permeability to the pre-beta-like particles suggests a complex mechanism of Prodectin antiatherogenic action. This mechanism probably includes and activation of biological oxidation and bioenergetics, an increase of cAMP in the vascular wall, resp. a decrease of contractility of endothelial cells; an inhibition of thrombotic processes and of lipoprotein infiltration of the arterial wall.
D000818:Animals; D001011:Aorta / Q000201:enzymology; D001161:Arteriosclerosis / Q000188:drug therapy*; D002219:Carbamates / Q000627:therapeutic use*; D002791:Cholesterol, Dietary / Q000008:administration & dosage; D008055:Lipids / Q000097:blood; D008074:Lipoproteins / Q000097:blood; D008297:Male; D011727:Pyridinolcarbamate / Q000627:therapeutic use*; D011817:Rabbits; D051381:Rats
D002219:Carbamates; D002791:Cholesterol, Dietary; D008055:Lipids; D008074:Lipoproteins; D011727:Pyridinolcarbamate